SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 85.78 |
| Enterprise Value ($M) | 0.98 |
| Book Value ($M) | 83.86 |
| Book Value / Share | 0.93 |
| Price / Book | 1.02 |
| NCAV ($M) | 83.60 |
| NCAV / Share | 0.93 |
| Price / NCAV | 1.03 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.36 |
| Return on Assets (ROA) | -1.88 |
| Return on Equity (ROE) | -2.54 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 36.91 |
| Current Ratio | 36.91 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 86.07 |
| Assets | 86.33 |
| Liabilities | 2.47 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Franklin Resources Inc | |||
| 13G | MPM Oncology Impact Management LP | |||
| 13G/A | Great Point Partners Llc | 9.25 | -6.53 | |
| 13G | Blue Owl Capital Holdings LP | 7.22 | ||
| 13G/A | Avidity Partners Management LP | 9.90 | 0.00 | |
| 13G/A | Hudson Bay Capital Management LP | 1.32 | 0.00 | |
| 13G | Nextech Crossover I GP S.a r.l. | 9.90 | ||
| 13G | Deep Track Capital, LP | 9.89 | ||
| 13G/A | Affinity Asset Advisors, LLC | 2.06 | -62.79 | |
| 13G/A | Lehr Martin A. | 8.80 | ||
| 13G | Opaleye Management Inc. | 5.14 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 16,778 | 88,845 | 18.88 | |
| 77,736 | 175,805 | 44.22 | |
| 113,512 | 364,040 | 31.18 | |
| 163,391 | 321,022 | 50.90 | |
| 8,521 | 34,694 | 24.56 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CLRB – Cellectar Biosciences, Inc. | CMPX – Compass Therapeutics, Inc. |
| CNSP – CNS Pharmaceuticals, Inc. | COCP – Cocrystal Pharma, Inc. |
| COEP – Coeptis Therapeutics Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io